Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.

BACKGROUND Current staging systems for unresectable or metastatic neuroblastoma do not reliably predict responses to chemotherapy in infants under 1 year of age. Previous studies have indicated that the DNA content, or ploidy, of malignant neuroblasts can discriminate between good and poor responders in this group of patients, but the clinical utility of ploidy assessment has remained in question. PURPOSE We tested, in a prospective nonrandomized study, the hypothesis that neuroblast ploidy could be used as the sole guide for treatment selection in infants with unresectable or metastatic tumors and could differentiate between those who would respond to our previous standard regimen and those who would benefit from an immediate switch to another therapy. METHODS One hundred seventy-seven infants were enrolled in this trial. Five of these infants were subsequently excluded (two ineligible, two lacking ploidy information, and one protocol violation); therefore, 172 patients were included in the study. One hundred thirty infants with hyperdiploid tumors (DNA index > 1.0; better prognosis in retrospective studies) were treated with a well-tolerated regimen of cyclophosphamide (150 mg/m2 per day orally or intravenously on days 1-7) and doxorubicin (35 mg/m2 intravenously on day 8). Forty-two infants with diploid tumors (DNA index = 1.0; worse prognosis in retrospective studies) received cisplatin (90 mg/m2 intravenously on day 1) and teniposide (100 mg/ m2 intravenously on day 3) after an initial course of cyclophosphamide plus doxorubicin. Statistical end points were response and long-term survival. In addition, we assessed within each ploidy group (i.e., patients with hyperdiploid tumors and those with diploid tumors) the prognostic significance of NMYC gene copy number, tumor stage, and other variables commonly measured in this disease. RESULTS Of the 127 assessable infants with hyperdiploid tumors, 115 (91%) had complete responses--85 after receiving five courses of cyclophosphamide plus doxorubicin and 30 after receiving further therapy including cisplatin plus teniposide. The 3-year survival estimate for the entire hyperdiploid group was 94% (95% confidence interval [CI] = 89%-98%). Nineteen (46%) of 41 assessable infants with diploid tumors were complete responders. The overall 3-year survival estimate for this group was 55% (95% CI = 39%-70%). Prognostic factor analysis indicated that NMYC gene amplification and an elevated serum lactate dehydrogenase level were statistically significant markers of higher risk disease within the diploid group (two-sided P values of .005 and .003, respectively). Only NMYC was predictive in the hyperdiploid group (P = .003). CONCLUSION Use of a prognostic staging system based on tumor cell ploidy, augmented with the NMYC gene copy number and serum level of lactate dehydrogenase, would very likely improve the treatment of infants with unresectable or metastatic neuroblastoma. Patients with diploid tumors characterized by an amplified NMYC locus represent a particularly unfavorable risk group that may benefit from innovative new therapies.

[1]  F. Behm,et al.  Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. , 1996, The Journal of clinical investigation.

[2]  S. Cohn,et al.  Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.

[3]  Rogier Versteeg,et al.  Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.

[4]  T. Rabbitts,et al.  Chromosomal translocations in human cancer , 1994, Nature.

[5]  A. Cantor,et al.  Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[7]  A. Cantor,et al.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. , 1993, The New England journal of medicine.

[8]  D. Campana,et al.  Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma. , 1992, Human gene therapy.

[9]  J. Shuster,et al.  Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: a Pediatric Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Shuster,et al.  Serum Lactate Dehydrogenase in Childhood Neuroblastoma A Pediatric Oncology Group Recursive Partitioning Study , 1992, American journal of clinical oncology.

[11]  J. Shuster,et al.  Age‐linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the pediatric oncology group , 1992, Cancer.

[12]  J. Shuster,et al.  SERUM LACTATE DEHYDROGENASE IN CHILDHOOD NEUROBLASTOMA , 1992 .

[13]  J. Shuster,et al.  AGE LINKED PROGNOSTIC CATEGORIZATION BASED ON ANEW HISTOLOGIC GRADING SYSTEM OF NEUROBLASTOMA , 1992 .

[14]  W. Furman,et al.  Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St Jude Children's Research Hospital experience, 1962 to 1988. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A T Look,et al.  Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Cheung,et al.  Immunotherapy. Neuroblastoma as a model. , 1991, Pediatric clinics of North America.

[17]  W. Crist,et al.  Common solid tumors of childhood. , 1991, The New England journal of medicine.

[18]  J. Bourhis,et al.  Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. , 1991, Progress in clinical and biological research.

[19]  B. Amendola Principles and Practice of Pediatric Oncology , 1990 .

[20]  G. Bonadonna,et al.  The pathologist and the clinical oncologist: a new effective partnership in assessing tumor prognosis. , 1989, European journal of cancer & clinical oncology.

[21]  P. Pizzo,et al.  Principles and Practice of Pediatric Oncology , 1989 .

[22]  B. Achinstein,et al.  Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.

[23]  J. Shuster,et al.  Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Zucker,et al.  Phase II studies of combinations of drugs with high dose carboplatin in neuroblastoma (800 mg/m2 to 1 g 250/m2): a report from the LMCE group. , 1988, Progress in clinical and biological research.

[25]  C. Patte,et al.  Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Schnipper,et al.  Clinical implications of tumor-cell heterogeneity. , 1986, The New England journal of medicine.

[27]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[28]  H. Sather,et al.  Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. , 1985, Cancer research.

[29]  H. B. Marsden,et al.  Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. , 1984, Journal of the National Cancer Institute.

[30]  A. Look,et al.  Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. , 1984, The New England journal of medicine.

[31]  S. Sallan,et al.  Improved prognosis for infants with stage IV neuroblastoma. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[33]  J. Trent,et al.  Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour , 1983, Nature.

[34]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[35]  A. Green,et al.  Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma , 1981, Cancer.

[36]  W. Evans,et al.  Clinical evaluation of sequentially scheduled cisplatin and vm26 in neuroblastoma: Response and toxicity , 1981, Cancer.

[37]  A. Evans,et al.  Do infants with stage IV-S neuroblastoma need treatment? , 1981, Archives of disease in childhood.

[38]  J. Quinn,et al.  Serum lactic dehydrogenase, an indicator of tumor activity in neuroblastoma. , 1980, The Journal of pediatrics.

[39]  J. Fraser,et al.  TREATMENT OF EARLY BREAST CANCER , 1978, The Lancet.

[40]  A. Green,et al.  Correlation of cell kinetic and clinical response to chemotherapy in disseminated neuroblastoma. , 1977, Cancer research.

[41]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[42]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[43]  J. Wendt Study Group , 1971 .

[44]  A. Evans,et al.  A proposed staging for children with neuroblastoma. Children's cancer study group A , 1971, Cancer.

[45]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .